AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Alvotech Wins UK High Court Case, Clears Path for AVT06 Biosimilar Launch
ByAinvest
Monday, Nov 10, 2025 7:46 am ET1min read
Alvotech has won a legal battle in the UK High Court against Regeneron Pharmaceuticals and Bayer AG, allowing Alvotech to sell its Eylea biosimilar, AVT06, in the UK and European Economic Area. The court rejected the injunction request to block Alvotech's manufacturing of AVT06, paving the way for commercial launches after the expiry date of Supplementary Protection Certificates for Eylea on November 23, 2025. Alvotech shares rose 5.60% to $6.03 in premarket trading.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet